Logo Asphalion

ARDAT project update

The team behind the ARDAT project is trying to answer some of the most perplexing questions surrounding viral gene and cell therapy, in the hope of getting us closer to new treatments for rare diseases. ARDAT wants to know more about the behaviour of gene and cell therapy treatments, delivered by viral vectors, once they’re inside the body.

The team behind the ARDAT project is trying to answer some of the most perplexing questions surrounding viral gene and cell therapy, in the hope of getting us closer to new treatments for rare diseases. ARDAT wants to know more about the behaviour of gene and cell therapy treatments, delivered by viral vectors, once they’re inside the body.
March 5, 2021

#H2020 | #AdvancedTherapies (#ARDAT) project news.

Innovative Medicines Initiative (IMI) has recently published an update on the #ARDAT project: viruses can be hijacked to help cure rare diseases, but the immune system keeps fighting back. The team behind the ARDAT project is trying to answer some of the most perplexing questions surrounding viral gene and cell therapy, in the hope of getting us closer to new treatments for rare diseases. ARDAT wants to know more about the behaviour of gene and cell therapy treatments, delivered by viral vectors, once they’re inside the body.

As a reminder, the ARDAT Consortium, led by Pfizer and the The University of Sheffield and supported by Europe’s Innovative Medicines Initiative (IMI), aims to help standardize and accelerate the development of Advanced Therapy Medicinal Products (#ATMPs), providing tools to advance the knowledge in the field of viral gene/cell therapy to accelerate the development of new treatments for rare diseases and allowing potentially transformative treatments to reach patients sooner.

This 5-year European consortium brings together the leading expertise of 34 academic, non-profit and private organizations including ASPHALION, which will provide continuous #regulatorysupport to all partners during the life of the project and co-lead the regulatory work package 5 (engagement with regulators and database development).

ASPHALION is proud and excited to participate in the consortium and looks forward to a challenging and fruitful collaboration with all partners. For more information on ARDAT, please visit: www.ardat.org #horizon2020

Read here the complete ARDAT project update new.

Search News & Events

  • Filter by category

Share

Related news and events

In2Sight | 4th annual meeting 3RS congress

At ASPHALION, we are part of the IN2SIGHT consortium, an EU-funded project, and we are delighted to be currently participating in the 4th annual meeting

Course | Regulatory aspects of vaccine development

TRANSVAC2 supported innovation for both prophylactic and therapeutic vaccine development by providing high-quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. TRANSVAC also offered training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.

ASPHALION HIGHLIGHTS Q2 2023

A lot of things have happened during these past three months. We received an award from AEFI as most engaged Company with its employees’ traning;

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting